Impact of Severe COVID-19 on Accelerating Dementia Onset: Clinical and Epidemiological Insights

Sasha Mukhija, MD[1,2,3], Max Sunog[1], Colin Magdamo[1,2], Mark W. Albers, MD, PhD[1,2]

Author Affiliations

[1]Neurology Department, Massachusetts General Hospital, Boston, USA (Mukhija, Sunog, Magdamo, Albers); [2]Laboratory of Systems Pharmacology, Harvard Medical School, Boston, USA (Mukhija, Magdamo, Albers); [3]Universitätsspital Zürich, Zürich, Switzerland (Mukhija)

Corresponding author: Mark W. Albers, MD, PhD, MassGeneral Institute for Neurodegenerative Disease, 114 16th Street, No. 2003 Charlestown, MA 02129

(albers.mark@mgh.harvard.edu)

Key points

Question Do individuals hospitalized for severe COVID-19 have a higher incidence of new-onset cognitive impairment compared to those hospitalized for other conditions?

Findings In this retrospective study of 221613 hospitalized patients, including 6454 hospitalized due to COVID-19, a higher incidence of new-onset cognitive impairment was observed among COVID-19 patients.

Meaning

Early recognition and diagnosis of dementia in individuals with severe COVID-19 are crucial for optimizing long-term patient outcomes.

Abstract

Importance

Severe COVID-19 infection has been associated with neurological complications, but its role in accelerating cognitive decline remains unclear.

Objective

To determine whether individuals hospitalized for severe COVID-19 exhibit a higher incidence of new onset cognitive impairment compared to those hospitalized for other conditions.

Design

A retrospective study emulating a target trial using Mass General Brigham electronic health records (March 2020-August 2024). The causal effect of COVID-19 hospitalization was estimated via cumulative incidence functions accounting for the competing risk of death.

Setting

Multicenter hospital-based study across the Mass General Brigham healthcare system.

Participants

A total of 221613 hospitalized patients met the eligibility criteria, including 6454 (2.0%) admitted due to COVID-19 and 215159 (98.0%) for all other conditions. Patients were excluded if they had less than three months of follow-up (due to censoring, cognitive impairment, or death), were younger than 55 years at baseline, or had no prior visit to Mass General Brigham in the year before baseline.

Main Outcomes and Measures

The primary outcome was new-onset cognitive impairment, identified via ICD codes and dementia medication prescriptions. The primary analysis estimated the hazard ratio for cognitive impairment with COVID-19 hospitalization relative to other hospitalizations, along with the risk difference at 4.5 years estimated via cumulative incidence functions. Inverse propensity score weighting was used to balance covariates (age, sex, comorbidities, hospitalization period).

Results

Among eligible patients (mean [SD] age, 69.55 [9.42] years, 55% female), those hospitalized for COVID-19 were significantly older and had more comorbidities (p < 0.05). COVID-19

hospitalization was associated with a higher risk of developing cognitive impairment (Hazard Ratio: 1.14 [95% CI: 1.02-1.30], P = 0.018). At 4.5 years, the cumulative incidence of cognitive impairment was 12.5% [95% CI: 11.3-13.5] in the COVID-19 group, compared to 11.6% [95% CI: 11.1-12.1] in the non-COVID-19 group.

Conclusions and Relevance

Severe COVID-19 infection was associated with an elevated risk of developing clinically recognized cognitive impairment. Future studies are needed to validate findings in other health care settings. Early screening and intervention for cognitive decline may help optimize long-term outcomes for COVID-19 patients.

Introduction

COVID-19, caused by the SARS-CoV-2 virus, emerged in late 2019 as a global pandemic with profound and widespread effects on human health. The virus has infected more than 700 million people worldwide[1] and primarily spreads through respiratory droplets[2]. Infection occurs when non-infected individuals are exposed to these droplets via inhalation or contact with contaminated surfaces[2]. Initially characterized by acute respiratory symptoms, it soon became evident that the virus affects multiple organ systems[3], leading to a diverse array of complications and even long-term consequences[4].

Long COVID, also known as PASC (post-acute sequelae of SARS-CoV-2), has affected about 70 million people worldwide[5]l. The World Health Organization defines PASC as a condition where symptoms last at least 3 months after the acute COVID-19 infection and cannot be explained by an alternative diagnosis[6,7]. Symptoms described as "Long COVID" include fatigue, cognitive dysfunction and issues with memory, often referred to as "brain fog"[8]. Long-Covid is more prevalent in people who were hospitalized and suffered from severe Covid-19 infection.[9–11] As the pandemic progressed, the impact of COVID-19 on the nervous system garnered significant attention[12–14]. A substantial proportion of patients have reported neurological and cognitive symptoms, ranging from mild headaches to severe neuronal degeneration[15]. SARS-CoV-2 is highly pathogenic, capable of infecting various cell types and tissues. However, it remains unclear whether the diverse symptoms result from viral persistence in infected tissues, dysregulated systemic inflammation, or widespread microangiopathy that often leads to microcirculatory thrombi [4,16].

In approximately one-third of patients suffering from severe COVID-19, neurological symptoms occur. These symptoms include headaches, paresthesias, strokes, smell loss and neuronal degeneration[4,12,17,18].

While mounting evidence indicates that SARS-CoV2 is not neurotropic, SARS-CoV2 infection of the respiratory tract has been proposed to affect the CNS through several indirect mechanisms, including angiopathy and persistent neuroinflammation[19].

SARS-CoV-2 enters the body by attaching to healthy cell membranes via the angiotensin-converting enzyme 2 (ACE2) receptor, which is present in many organ systems[20]. A proposed mechanism for SARS-CoV-2-related olfactory dysfunction involves direct viral targeting of non-neuronal sustentacular support cells in the nasal epithelium that express both the ACE2 receptor and a host cell protease, TMPRSS2 (transmembrane protease serine 2). Once infected, these cells may disrupt the electrophysiological and biochemical homeostasis of nearby olfactory sensory neurons leading to smell distortion. The invasion of SARS-CoV-2 into healthy cells reduces the bioavailability of ACE2 receptors, potentially leading to organ injury through a cytokine storm—an uncontrolled, non-specific inflammatory response—along with increased coagulation, fibrinolysis, and myocardial injury[21,22]. Additionally, conventional MRI scans of individuals with COVID-19 have revealed localized abnormalities in olfactory-eloquent brain regions, suggesting selective susceptibility[4,23]. On the other hand impaired olfaction has been shown to be associated with faster cognitive decline[24].

The mechanisms underlying memory impairment associated with COVID-19 are not yet fully understood, though several hypotheses have been proposed. Neuroinflammatory markers have been identified in the brains of more than 80% of COVID-19 patients, suggesting that inflammatory processes may contribute to the observed neurological symptoms[25]. It is postulated that viral particles or cytokines may enter the brain by direct transport along the neuronal pathways from the nasal cavity through the cribriform plate and into the olfactory bulb[14,26]. While sudden-onset anosmia or hyposmia (complete or partial loss of smell) has been widely reported as a specific indicator of early infection, the exact mechanisms by which the olfactory system is impaired remain unclear[4]. Interestingly, hyposmia is also an early symptom of Alzheimer's disease, highlighting a potential overlap in pathophysiologic mechanisms[26].

Emerging evidence also indicates that a pathway leading to tau hyperphosphorylation, typically associated with Alzheimer's disease, is activated in COVID-19 patients. This activation is believed to occur through inflammatory signaling by activating the NLRP3 inflammasome and oxidative stress triggered by SARS-CoV-2 infection[27,28]. In general dementia related biomarkers have been found in patients with acute or severe SARS-CoV-2 infection[29–31]. This includes reduced levels of plasma Aβ42, elevated levels of phospho-tau181 and neurofilament light chain – markers associated with Alzheimer's disease in blood or cerebrospinal fluid[32,33,34]. This further emphasizes the potential long-term neurological impacts of the viral infection of the nasal epithelium[35]. With emerging evidence of increased biomarkers of AD and other neurodegenerative diseases following SARS-CoV2 infection, we tested the hypothesis that SARS-CoV2 infection would increase the risk of being diagnosed with cognitive impairment in subsequent years.

Methods

Study population

This study is a multi-center, EHR-based, retrospective target trial emulation (TTE). Patients aged 55 years and older who were hospitalized at Mass General Brigham (MGB) in Boston, USA, between March 1, 2020, and April 29, 2024, were included. After applying exclusion criteria to the total of 1292054 patients hospitalized, 221613 patients remained (Figure 1). The primary outcome was the diagnosis of a new-onset cognitive impairment. For the purposes of this analysis, new onset cognitive impairment includes all forms of clinically diagnosed dementia, as well as milder forms of cognitive impairment, including mild cognitive impairment (MCI) and documented memory loss (Supplementary File 1). This was determined based on a union between International Classification of Diseases (ICD) codes ICD-9 and ICD-10 expertly curated, for memory-related conditions such as memory loss, mild cognitive impairment, Alzheimer's disease, and related dementias (see Supplementary File 1), as well as the prescription of a dementia medication - galantamine (Razadyne, Razadyne ER), donepezil (Aricept), rivastigmine (Exelon) or memantine (Namenda). Demographic characteristics, comorbidities, and the time periods of hospitalization during different SARS-CoV-2 strain predominance among the included 221613 hospitalized patients at Mass General Brigham were compared. This included 6454 (2.0%) patients admitted due to COVID-19 and 215159 (98%) patients hospitalized for other reasons. Patients hospitalized due to COVID-19 showed significant differences in several characteristics compared to those hospitalized for other reasons (Table 1). Use of data for this study was approved by the institutional review board (IRB) of MGB (Protocol 2023P000604).

Target Trial Emulation

Causal effects of interventions are typically tested through randomized controlled trials (RCTs), but RCTs are not always feasible. For example, assigning participants to a COVID-19 infection

would be unethical, making an RCT impossible. Instead, the causal effect of COVID-19 hospitalization versus hospitalization for other reasons can be examined using the TTE framework, which retrospectively mimics an RCT using electronic health records.

In a TTE, eligible patients are identified based on predefined criteria in the EHRs. Their records determine the baseline date and treatment assignment (e.g., COVID-19 hospitalization), while follow-up encounters establish outcomes or censoring dates. Since treatment arms in a TTE are not randomized, inverse propensity of treatment weighting (IPTW) is applied to reduce confounding. IPTW ensures that observed differences are attributable to the intervention rather than preexisting factors, provided all relevant confounders are measured and no patient is entirely ineligible for either treatment arm.[36,37]

Statistical assessment

Data for this study were obtained from the Enterprise Data Warehouse (EDW) at Mass General Brigham using Microsoft Structured Query Language (SQL) Server Management Studio. Secondary analyses were conducted using RStudio (Version 4.3).

To account for potential confounding factors and ascertain the causal effect of interest, IPTW was used to balance the group hospitalized due to COVID-19 with the group hospitalized for other reasons across several covariates, including sex, age, comorbidities (e.g., hypertension, diabetes), and period of hospitalization (Pre-Alpha, Alpha, Delta, Omicron, and Post-Omicron Covid Strain). The efficacy of the propensity score weighting is demonstrated through the successful balancing of covariates between the groups. The primary outcome of interest was the diagnosis of new onset cognitive impairment, and the statistical significance of differences between groups was assessed using hazard ratios (HRs) with 95% CIs derived from Cox proportional hazards models[38].

The competing risk of death was accounted for in the cumulative incidence functions, which estimated the probability of new-onset cognitive impairment and of death before cognitive impairment over a 4.5-year period[39].

Results

Out of the 221613 patients included in the study, 6454 (2%) were hospitalized due to COVID-19. Patients hospitalized due to COVID-19 have a significantly higher risk of developing new onset cognitive impairment compared to those hospitalized for other reasons. The hazard ratio (HR) for cognitive impairment among hospitalized COVID-19 patients was 1.14 (95% CI: 1.02–1.28; p = 0.017) on average over 4.5 years of follow up (Figure 2).

Increasing age conferred a significant increase in risk of cognitive impairment risk (HR 1.06 per year, 95% CI 1.057–1.061, p < 0.001), and female sex was also associated with elevated risk (HR 1.12, 95% CI 1.08–1.17, p < 0.001).

Among comorbidities, COPD (chronic obstructive pulmonary disease) (HR 1.22, 95% CI 1.15–1.29, p < 0.001), diabetes (HR 1.23, 95% CI 1.18–1.29, p < 0.001), cardiovascular disease (HR 1.09, 95% CI 1.05-1.14, p>0.001), hypertension (HR 1.10, 95% CI 1.05–1.15, p < 0.001), and history of stroke (HR 1.44, 95% CI 1.35–1.53, p < 0.001) were each significantly associated with greater risk of cognitive impairment risk. In contrast, being merely overweight (HR 0.99, 95% CI 0.95–1.03, p = 0.571) and being obese (HR 0.96, 95% CI 0.92–1.00, p = 0.069) were not statistically significant predictors.

Among those with recorded educational status, the level of attainment had no significant effects. Compared to high school education, a college-level education correlated with a decreased hazard of cognitive impairment (HR 0.96, 95% CI 0.92–1.00, p =0.057), whereas a graduate-level education was marginally protective (HR 0.98, 95% CI 0.92–1.04, p = 0.460). Missing data on education showed a significant effect (HR 0.86, 95% CI 0.81–0.90, p <0.001).

Finally, relative to the reference period which is the time during the Alpha-strain of SARS-CoV-2, the pre-Alpha era was associated with a significantly higher increased risk for cognitive

impairment (HR 1.05, 95% CI 1.00–1.10, p = 0.037), whereas the Delta-period estimate (HR 1.01, 95% CI 0.95–1.08, p = 0.697) and subsequent viral waves (Omicron, Post-Omicron) did not show consistent or significant deviations from the reference risk (CIs crossing or approaching unity).

In summary, COVID-19 hospitalization was associated with a significant elevation in the hazard of new onset cognitive impairment, over and above known risk factors such as older age, comorbid cardiopulmonary conditions, and diabetes.

The propensity score-weighted analysis demonstrated effective balancing of covariates.

After adjusting for the competing risk of death, the cumulative probability of being diagnosed with cognitive impairment over a 4.5-year follow-up period was higher among patients hospitalized due to COVID-19 compared to those hospitalized for other reasons. Specifically, the probability of developing cognitive impairment was 12.5% (95% CI: 11.3%–13.5%) in the COVID-19 cohort, compared to 11.6% (95% CI: 11.1%–12.1%) in the cohort hospitalized for other conditions (Figure 3). The COVID-19 cohort exhibited a cumulative incidence of death of 16.2% (95% CI: 15.0%–17.6%) over the follow-up period, compared to 16.3% (95% CI: 15.5%–17.1%) in the non-COVID hospitalized cohort.

Discussion

Using causal inference approaches, we tested the hypothesis that patients hospitalized due to COVID-19 were more likely to develop a cognitive impairment relative to patients who were hospitalized concurrently for other reasons. After balancing the two treatment arms using IPTW and controlling for the competing risk of death, we found that patients with severe COVID had an elevated risk of being diagnosed with cognitive impairment 3 months or later after baseline, relative to patients concurrently hospitalized for other reasons. The divergence between the cumulative incidence curves for new-onset cognitive impairment between the two groups becomes particularly evident after year 2, suggesting that the long-term neurological impact of COVID-19 hospitalization may manifest progressively over time.

Importantly, these results were derived using a competing risk model, which accounts for the likelihood of death as a competing event. This adjustment ensures that the observed differences in risk for cognitive impairment are not confounded by variations in mortality rates between the groups.

When stratifying by cause of hospitalization, individuals hospitalized due to COVID-19 not only had an elevated risk of cognitive impairment but also a greater probability of death.

The competing risk framework highlights that, despite the increased mortality in the COVID-19 group, the risk for cognitive impairment remains significantly elevated, indicating that the observed cognitive decline is not attributable to survival bias. The greater risk of new onset cognitive impairment among those hospitalized with COVID-19, despite the competing risk of death, underscores the long-term neurological consequences of viral infection with severe symptoms. A UK based study of hospitalized COVID-19 patients has identified the most common neurologic conditions as being anosmia, stroke, delirium, brain inflammation, encephalopathy, primary psychiatric syndromes and peripheral nerve syndromes[37]. Many of

these neurologic sequelae are also risk factors for age-related neurodegenerative diseases.

These findings support the hypothesis that mechanisms such as neuroinflammation, cerebrovascular complications, and direct viral effects on the brain contribute to cognitive decline in COVID-19 patients. This underscores the critical need for long-term follow-up care and cognitive monitoring for COVID-19 survivors.

Additionally, individuals with pre-existing comorbidities -- such as hypertension and diabetes -- and older adults are at heightened risk, suggesting that these populations may require more intensive surveillance and early intervention. Other studies have also shown that plasma biomarker changes (Aβ42, and phospho-tau181) were larger in patients that were hospitalized due to their COVID-19 infection or had previously diagnosed hypertension[34]. It is postulated that these conditions might involve pre-existing ACE-2 deficiencies predating SARS-CoV-2 infection. As a result, the risk of a more severe infection is increased due to a further reduced bioavailability of ACE2 receptors[40–42].

While evidence for increased dementia rates following severe SARS-CoV-2 infection has previously been reported [28,30,43], our study provides novel contributions in both scale and methodology. By leveraging a large, longitudinal cohort with up to 4.5 years of follow-up and using non-COVID hospitalized controls, we were able to isolate the impact of severe COVID-19 beyond hospitalization alone. Advanced causal inference methods, including inverse propensity score weighting and competing risk modeling, allowed us to address confounding and the competing risk of death.

The findings contribute to a growing body of evidence indicating that COVID-19 may have long-lasting effects on brain health, especially in vulnerable groups. This is particularly concerning

given the widespread prevalence and enduring impact of the virus, highlighting the necessity for healthcare systems to adapt and prepare for potential long-term increases in dementia cases.

Moreover, the biological mechanisms linking SARS-CoV-2 infection to cognitive decline merit further investigation. Neuroinflammatory markers identified in COVID-19 patients suggest that inflammatory processes play a crucial role. Studies have shown that COVID-19 could potentially exacerbate neuroinflammation and contribute to neurodegeneration, highlighting the fact that peripheral infection and its subsequent immune response could be responsible for the neuropathology[34,44].

The observed association between severe COVID-19 and subsequent cognitive impairment underscores the need for continued research to elucidate the underlying pathways. Understanding these connections is essential for developing targeted therapeutic strategies to mitigate the long-term cognitive impacts of COVID-19.

Limitations

The study's retrospective design may introduce limitations inherent in the use of EHRs, caused by incomplete data and inaccuracies in coding, which were exacerbated by the disruption caused by the pandemic. To specifically investigate the effect of severe COVID-19, patients were only assigned to the treatment arm if a confirmed COVID-19 infection was listed as a reason for hospitalization. However, patients in the control arm may have had Covid-19 infection that did not lead to hospitalization prior to baseline; mild, untested, or unrecorded COVID-19 infection during their hospitalization; or have contracted Covid-19 in the hospital after admission. While inverse propensity score weighting was employed to balance observed covariates, residual confounding due to unmeasured factors, such as genetic predispositions or lifestyle factors, cannot be entirely excluded. The cohort is predominantly composed of patients from a single healthcare system (Mass General Brigham), which may limit the generalizability of the findings to other populations or healthcare settings. This study may have measurement errors in

its primary outcome. Dementia is often underdiagnosed and under-recorded[45]. Patients and families may not report symptoms, and physicians may not routinely screen for cognitive health. Even when symptoms are noted, diagnostic codes or prescriptions used as proxies may be missing or appear late. In some cases, dementia may also be overcoded[46].

Conclusion

In conclusion, our findings suggest that severe COVID-19 may accelerate the onset of cognitive impairment after accounting for the competing risk of death. Early clinical recognition and diagnosis of dementia in this population are critical for improving long-term patient outcomes. Screening tools that assess the neural processing of smells in patients who had COVID-19 could serve as an important method for monitoring cognitive function and early neurological changes[47]. At home preclinical cognitive tests, such as BRANCH (Boston Remote Assessment for Neurocognitive Health), may be sensitive to detect subtle declines[48].

The observed increase in dementia risk, although modest, carries significant clinical implications given the substantial number of COVID-19 hospitalizations globally. It emphasizes the necessity for long-term follow-up care and cognitive monitoring for COVID-19 survivors, especially those at heightened risk due to pre-existing health conditions. Establishing biomarkers for predicting subsequent cognitive decline after SARS-CoV2- infection might be a promising strategy[28].

Further research is essential to replicate these results in other health care systems and understand the relationship of vaccination to mitigate the risk of dementia. Elucidating the specific mechanisms involved in neurodegenerative disease progression could guide the development of targeted interventions aimed at preventing or mitigating dementia and other long-term neurological diseases. This could improve the quality of life for COVID-19 survivors.

Conflict of Interest

All authors declare no competing interests or conflicts.

Author Contribution

Max Sunog and Colin Magdamo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Sasha Mukhija, Max Sunog, Colin Magdamo and Mark W. Albers designed the study, analyzed data and edited/wrote the paper.

Funding/Support: S.M. was supported by a Fulbright Fellowship. This study was funded by R01 AG058063 and U01DC019579 (awarded to M.W.A.)

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data sharing statement

See Supplement File 2

Reference List

1. Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023;329(22):1934. doi:10.1001/jama.2023.8823

2. Li H, Wang Y, Ji M, et al. Transmission Routes Analysis of SARS-CoV-2: A Systematic Review and Case Report. *Front Cell Dev Biol*. 2020;8:618. doi:10.3389/fcell.2020.00618

3. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019

4. Xydakis MS, Albers MW, Holbrook EH, et al. Post-viral effects of COVID-19 in the olfactory system and their implications. *Lancet Neurol*. 2021;20(9):753-761. doi:10.1016/S1474-4422(21)00182-4

5. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol*. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2

6. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. *Science*. 2022;375(6585):1122-1127. doi:10.1126/science.abm8108

7. Committee on Examining the Working Definition for Long COVID, Board on Health Sciences Policy, Board on Global Health, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. *A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences*. (Fineberg HV, Brown L, Worku T, Goldowitz I, eds.). National Academies Press; 2024:27768. doi:10.17226/27768

8. Geng LN, Erlandson KM, Hornig M, et al. 2024 Update of the RECOVER-Adult Long COVID Research Index. *JAMA*. Published online December 18, 2024. doi:10.1001/jama.2024.24184

9. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. 2020;77(6):683. doi:10.1001/jamaneurol.2020.1127

10. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. *Neurology*. 2020;95(8). doi:10.1212/WNL.0000000000009937

11. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. *Ann Clin Transl Neurol*. 2020;7(11):2221-2230. doi:10.1002/acn3.51210

12. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun*. 2020;87:18-22. doi:10.1016/j.bbi.2020.03.031

13. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. *The Lancet Neurology*. 2020;19(11):919-929. doi:10.1016/S1474-4422(20)30308-2

14. Tyagi K, Rai P, Gautam A, et al. Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders. *Eur J Med Res*. 2023;28(1):307. doi:10.1186/s40001-023-01293-2

15. Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. *Alz Res Therapy*. 2020;12(1):170. doi:10.1186/s13195-020-00744-w

16. Russell SJ, Parker K, Lehoczki A, et al. Post-acute sequelae of SARS-CoV-2 infection (Long COVID) in older adults. *Geroscience*. 2024;46(6):6563-6581. doi:10.1007/s11357-024-01227-8

17. Hampshire A, Azor A, Atchison C, et al. Cognition and Memory after Covid-19 in a Large Community Sample. *N Engl J Med*. 2024;390(9):806-818. doi:10.1056/NEJMoa2311330

18. Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. *Nat Med*. 2022;28(11):2406-2415. doi:10.1038/s41591-022-02001-z

19. Desforges M, Le Coupanec A, Brison E, Meessen-Pinard M, Talbot PJ. Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. *Adv Exp Med Biol*. 2014;807:75-96. doi:10.1007/978-81-322-1777-0_6

20. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res*. 2020;126(10):1456-1474. doi:10.1161/CIRCRESAHA.120.317015

21. Fajgenbaum DC, June CH. Cytokine Storm. *N Engl J Med*. 2020;383(23):2255-2273. doi:10.1056/NEJMra2026131

22. Offringa A, Montijn R, Singh S, Paul M, Pinto YM, Pinto-Sietsma SJ. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. *Eur Heart J Cardiovasc Pharmacother*. 2020;6(5):317-325. doi:10.1093/ehjcvp/pvaa053

23. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature*. 2022;604(7907):697-707. doi:10.1038/s41586-022-04569-5

24. Dintica CS, Marseglia A, Rizzuto D, et al. Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. *Neurology*. 2019;92(7). doi:10.1212/WNL.0000000000006919

25. Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. *Brain*. 2021;144(9):2696-2708. doi:10.1093/brain/awab148

26. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*. 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5

27. Shan D, Wang C, Crawford T, Holland C. Association between COVID-19 infection and new-onset dementia in older adults: a systematic review and meta-analysis. *BMC Geriatr*. 2024;24(1):940. doi:10.1186/s12877-024-05538-5

28. Gordon MN, Heneka MT, Le Page LM, et al. Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research. *Alzheimers Dement*. 2022;18(5):1038-1046. doi:10.1002/alz.12488

29. Kim KY, Shin KY, Chang KA. GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. *Cells*. 2023;12(9):1309. doi:10.3390/cells12091309

30. Frontera JA, Boutajangout A, Masurkar AV, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. *Alzheimer's & Dementia*. 2022;18(5):899-910. doi:10.1002/alz.12556

31. Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Biomarkers in long COVID-19: A systematic review. *Front Med*. 2023;10:1085988. doi:10.3389/fmed.2023.1085988

32. Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol Med*. 2019;11(12):e11170. doi:10.15252/emmm.201911170

33. Mattsson N, Andreasson U, Zetterberg H, Blennow K, for the Alzheimer's Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol*. 2017;74(5):557. doi:10.1001/jamaneurol.2016.6117

34. Duff EP, Zetterberg H, Heslegrave A, et al. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. *Nat Med*. Published online January 30, 2025. doi:10.1038/s41591-024-03426-4

35. Reiken S, Sittenfeld L, Dridi H, Liu Y, Liu X, Marks AR. Alzheimer's-like signaling in brains of COVID-19 patients. *Alzheimers Dement*. 2022;18(5):955-965. doi:10.1002/alz.12558

36. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. *Am J Epidemiol*. 2016;183(8):758-764. doi:10.1093/aje/kwv254

37. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41

38. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society Series B: Statistical Methodology*. 1972;34(2):187-202. doi:10.1111/j.2517-6161.1972.tb00899.x

39. Vakulenko-Lagun B, Magdamo C, Charpignon ML, Zheng B, Albers MW, Das S. causalCmprsk: An R package for nonparametric and Cox-based estimation of average treatment effects in competing risks data. *Comput Methods Programs Biomed*. 2023;242:107819. doi:10.1016/j.cmpb.2023.107819

40. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. *Eur J Intern Med*. 2020;76:14-20. doi:10.1016/j.ejim.2020.04.037

41. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. *JAMA Cardiol*. 2020;5(7):747-748. doi:10.1001/jamacardio.2020.1329

42. Pyne JD, Brickman AM. The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline. *Neurodegener Dis*. 2021;21(1-2):1-23. doi:10.1159/000518581

43. Shan D, Wang C, Crawford T, Holland C. Temporal association between COVID-19 infection and subsequent new-onset dementia in older adults (aged 60 years and above): a systematic review and meta-analysis. *The Lancet*. 2024;404:S73. doi:10.1016/S0140-6736(24)01987-1

44. Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous System. *Cell*. 2020;183(1):16-27.e1. doi:10.1016/j.cell.2020.08.028

45. 2020 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*. 2020;16(3):391-460. doi:10.1002/alz.12068

46. Østbye T, Taylor DH, Clipp EC, Scoyoc LV, Plassman BL. Identification of Dementia: Agreement among National Survey Data, Medicare Claims, and Death Certificates. *Health Services Research*. 2008;43(1p1):313-326. doi:10.1111/j.1475-6773.2007.00748.x

47. Jobin B, Magdamo C, Delphus D, et al. AROMHA Brain Health Test: A Remote Olfactory Assessment as a Screen for Cognitive Impairment. Published online August 6, 2024. doi:10.1101/2024.08.03.24311283

48. Weizenbaum EL, Hsieh S, Molinare C, et al. Validation of the multi-day Boston remote assessment of neurocognitive health (BRANCH) among cognitively impaired & unimpaired older adults. *The Journal of Prevention of Alzheimer's Disease*. 2025;12(3):100057. doi:10.1016/j.tjpad.2025.100057

Figure and Tables (4 out of max 5)

Table 1. Demographics, Comorbidities, and COVID-19 Strain Periods Among COVID-19

Hospitalized Patients vs. Non-COVID Patients Hospitalized for All Other Reasons

Covariates	Hospitalized for all other reasons (n= 215159)	Hospitalized due to COVID-19 (n=6454)	p
No. (%) female	118080 (55%)	3335 (52%)	<0.001
Age, mean (SD), years	69.53 (9.40)	70.29 (9.98)	<0.001
No. (%) with hypertension	122406 (57%)	4003 (62%)	<0.001
No. (%) with stroke	9590 (4%)	280 (4%)	0.649
No. (%) with COPD	15168 (7%)	577 (9%)	<0.001
No. (%) with obesity	80181 (37%)	2673 (41%)	<0.001
No. (%) with overweight	148371 (69%)	4474 (69%)	0.535
No. (%) with cardiovascular disease	45710 (21%)	1543 (24%)	<0.001
No. (%) with diabetes	38106 (18%)	1629 (25%)	<0.001
No. (%) with graduate education	23469 (11%)	535 (8%)	<0.001
No. (%) college education	90624 (42%)	2273 (35%)	<0.001
No. (%) with missing education	40023 (19%)	1182 (18%)	0.559
No. (%) during Time Period of Strain–Alpha (October 2020-June 2021)	43371 (20%)	1588 (25%)	<0.001
No. (%) during Time Period of Strain-Delta (July 2021-November 2021)	23559 (11%)	330 (5%)	<0.001
No. (%) during Time Period of Strain-Omicron (December 2021-Februar 2022)	10146 (5%)	712 (11%)	<0.001
No. (%) during Time Period of Strain-Post Omicron (March 2023-end of analysis August 2024)	85667 (40%)	2682 (42%)	<0.001
No. (%) during Time Period of Strain- Pre Alpha (March 2020-September 2020)	52416 (24%)	1142 (18%)	<0.001

Figure 1. Consortium Diagram with Inclusion and Exclusion Criteria

Figure 2. Hazard Ratios for Dementia Risk in COVID-19 vs. Non-COVID-19 Hospitalized

Patients Across Covariates

Hospitalized for COVID	1.14 (1.02 – 1.28)	0.017 *
Age at Hospitalization	1.06 (1.06 – 1.06)	<0.001 ***
Sex	1.12 (1.08 – 1.17)	<0.001 ***
Hypertension	1.10 (1.05 – 1.15)	<0.001 ***
Stroke	1.44 (1.35-1.53)	<0.001 ***
COPD	1.22 (1.15 – 1.29)	<0.001 ***
Obesity	.96 (.92 – 1.00)	0.069
Overweight	.99 (.95 – 1.03)	0.571
Cardiovascular Disease	1.09 (1.05 – 1.14)	<0.001 ***
Diabetes	1.23 (1.18 – 1.29)	<0.001 ***
Education – High School	reference	
Education – College	.96 (.92 – 1.00)	0.057
Education – Graduate	.98 (.92 – 1.04)	0.460
Education – Missing	.86 (.81 - .90)	<0.001 ***
COVID Variant at Baseline – Alpha	reference	
COVID Variant at Baseline – Delta	1.01 (.95 – 1.08)	0.697
COVID Variant at Baseline – Omicron	1.00 (.91 – 1.10)	0.983
COVID Variant at Baseline – Post-Omicron	1.05 (.99 – 1.11)	0.111
COVID Variant at Baseline – Pre-Alpha	1.05 (1.00 – 1.10)	0.037 *
Social Vulnerability Score (Socio-economic)	.90 (.78 – 1.06)	0.199
Social Vulnerability Score (Domestic Life)	.99 (.87 – 1.13)	0.849
Social Vulnerability Score (Racial/Ethnic)	1.12 (.97 – 1.31)	0.134
Social Vulnerability Score (Housing)	1.56 (1.34 – 1.83)	<0.001 ***

Figure 3. Cumulative Probability of Incident Cognitive Impairment and Death Over a 4.5-Year Period for COVID-19 vs. Non-COVID-19 Hospitalized Patients

Supplementary File 1

Code	Name
F03.91	Unspecified dementia with behavioral disturbance
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance
d290.43.1	Vascular dementia, With depressed mood
d290.42.1	Vascular dementia With delusions
F01.51	Vascular dementia with behavioral disturbance
290.20	Senile dementia with delusional features
290.3	Senile dementia with delirium
290.43	Arteriosclerotic dementia with depressive features
290.41	Arteriosclerotic dementia with delirium
290.21	Senile dementia with depressive features
290.12	Presenile dementia with delusional features
290.13	Presenile dementia with depressive features
290.42	Arteriosclerotic dementia with delusional features
290.2	Senile dementia with delusional or depressive features
294.21	Dementia, unspecified, with behavioral disturbance
294.11	Dementia in conditions classified elsewhere with behavioral disturbance
F03.9	Unspecified dementia
331.1	Pick's disease
d290.0.1	Senile Dementia Uncomp
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance
F03.90	Unspecified dementia without behavioral disturbance
G31.83	Dementia with lewy bodies
F01.50	Vascular dementia without behavioral disturbance
LPA99	Dementia-LMR 99
LPA867	Alzheimer's disease-LMR 867
ODA:YHAL6	Dementia-Oncall
d290.40.1	Vascular dementia, uncomplicated
LPA1009	Alzheimers disease-LMR 1009
G31.09	Other frontotemporal dementia
G31.01	Pick's Disease
ODA:WHMT3	Alzheimer's disease-Oncall
d331.0.3	Alzheimer's disease
d294.10.1	Dementia Conditions Classified Elsewhere w/o Behavioral Disturbances
d290.10.1	Presenile dementia
F03	Unspecified dementia

331.19	Other frontotemporal dementia
331.11	Pick's disease
331.82	Dementia with Lewy bodies
G30.8	Other alzheimer's disease
G30.9	Alzheimer's disease, unspecified
G30.0	Alzheimer's disease with early onset
G30.1	Alzheimer's disease with late onset
290.0	Senile dementia, uncomplicated
290.40	Arteriosclerotic dementia, uncomplicated
290.10	Presenile dementia, uncomplicated
290.11	Presenile dementia with delirium
290	Senile and presenile organic psychotic conditions
290.4	Arteriosclerotic dementia
290.1	Presenile dementia
294.10	Dementia in conditions classified elsewhere without behavioral disturbance
294.20	Dementia, unspecified, without behavioral disturbance
294.1	Dementia in conditions classified elsewhere
331.0	Alzheimer's disease
331.00	Alzheimer's disease
F02	Dementia in other diseases classified elsewhere
294.2	Dementia, unspecified
F01	Vascular dementia
G31.1	Senile degeneration of brain, not elsewhere classified
G31.9	Degenerative disease of nervous system, unspecified
331.2	Senile degeneration of brain
331.8	Other Cerebral Degeneration
331.9	Cerebral Degeneration, unspecified
G31.81	Alpers disease
G31.85	Corticobasal degeneration
G31.89	Other specified degenerative diseases of nervous system
331.89	Other Cerebral Degeneration
331	Other Cerebral Degenerations
290.9	Unspecified senile psychotic condition
290.8	Other specified senile psychotic conditions
294.9	Unspecified organic brain syndrome (chronic)
294.8	Other specified organic brain syndromes (chronic)
294	Other organic psychotic conditions (chronic)
438.0	Cognitive deficits as late effect of cerebrovascular disease
G31.84	Mild cognitive impairment, so stated

ODA:WLEN6	Cognitive impairment-Oncall
331.83	Mild cognitive impairment, so stated
F04	Amnestic disorder due to known physiological condition
780.93	Memory loss
R41.2	Retrograde amnesia
R41.3	Other amnesia
I69.211	Memory deficit following other nontraumatic intracranial hemorrhage
LPA730	Memory loss-LMR 730
LPA1404	Memory loss-LMR 1404
ODA:WLAG8	Memory loss-Oncall
I69.311	Memory deficit following cerebral infarction
I69.811	Memory deficit following other cerebrovascular disease
I69.911	Memory deficit following unspecified cerebrovascular disease
294.0	Amnestic syndrome
R41.81	Age-related cognitive decline
797	Senility without mention of psychosis
797.0	Senility without mention of psychosis
G30	Alzheimer's disease
G31.0	Frontotemporal dementia
G31.8	Other specified degenerative diseases of nervous system
F01.5	Vascular dementia without behavioral disturbance
F02.8	Dementia in other diseases classified elsewhere with behavioral disturbance
F01.A	Vascular Dementia, mild
F01.B	Vascular Dementia, moderate
F01.C	Vascular Dementia, severe
F02.A	Dementia in other diseases classified elsewhere, mild
F02.B	Dementia in other diseases classified elsewhere, moderate
F02.C	Dementia in other diseases classified elsewhere, severe
F03.A	Unspecified dementia, mild
F03.B	Unspecified dementia, moderate
F03.C	Unspecified dementia, severe

Supplement File 2

Data available: No

Additional Information

Explanation for why data not available: Researchers can obtain an anonymized version of the study dataset from the authors upon request and completion of the MGB Health data use agreement for the use of EDW data. This agreement ensures the privacy of MGB patients and compliance with US regulatory standards and has been approved by the MGB IRB. In addition, we provide a summary about patient data security and privacy. Patients who visit Mass General Brigham receive a HIPAA notice that states that their identifiable data may be used for research with proper Institutional Review Board approval. The patient has an opportunity to object to this usage of their data by seeking care outside of Mass General Brigham. The IRB classifies aggregate queries of online patient registries that are populated with appropriately obfuscated, de-identified/encrypted data, performed by authorized staff as a category of research that is exempt from IRB review. In addition, HIPAA privacy rules do not apply to de-identified information. Therefore, the Mass General Brigham Research Council determined that faculty, and those overseen directly by faculty, are approved for access to the Query Tool. However, with respect to the Detailed Data Wizard, the IRB must review and approve the release of identified and de-identified medical record data to researchers. In an effort to secure patient privacy and prevent a security breach, all patient identifiers are encrypted throughout the database.